Effect Allele / genotype (individuals studied) References
Bacterial infections HLA-E*01:01, 01:01 in donor
(77 unrelated donor-recipient pairs identically matched for HLA class I and II alleles)
[26]
Transplant related mortality at day 180 HLA-E*01:01, 01:01 in donor
(77 unrelated donor-recipient pairs identically matched for HLA class I and II alleles)
[26]
Protection from aGvHD HLA-E*01:03, 01:03 either in donor or in recipient
(187 HLA-identical sibling pairs)
[28]
Protection from TRM at day 180 HLA-E*01:03, 01:03 either in donor or in recipient
(187 HLA-identical sibling pairs)
[28]
Higher probability of overall survival HLA-E*01:03, 01:03 in patients
(83 HLA-matched donor-recipient pairs)
[29]
Disease free survival HLA-E*01:03, 01:03 in patients
(83 HLA-matched donor-recipient pairs)
[29]
Decreased incidence of transplant related mortality HLA-E*01:03, 01:03 in patients
(83 HLA-matched donor-recipient pairs)
[29]
Higher risk of GvHD HLA-E*01:01 and 01:03 unmatched in donor and recipient
(100 allogeneic donor-recipient pairs)
[30]
Higher survival rate Homozygotes HLA*01:03, 01:03
(100 allogeneic donor-recipient pairs)
[30]
Decreased risk of aGvHD (II-IV) HLA-E*01:03, 01:03 in donors
(121 unrelated donor-recipient pairs)
[31]
Decreased risk of overall aGvHD (cumulative incidence at 3 years) HLA-E*01:03, 01:03 in donors
(102 unrelated donor-recipient pairs)
[31]
Higher risk of relapse (cumulative incidence at 3 years) HLA-E*01:03 in donors
(124 unrelated donor-recipient pairs)
[31]
TRM (cumulative incidence at 189 days) HLA-E*01:03, 01:03 in donors was a risk factor, whereas the presence of HLA-E*01:01 alleles were protective
(124 unrelated donor-recipient pairs)
[31]
Lower risk of aGvHD and cGvHD HLA-E*01:03, 01:03 in patients
(56 HLA-E matched donor-recipient pairs)
[32]
Improved overall survival HLA-E*01:03, 01:03 in patients
(56 HLA-E matched donor-recipient pairs)
[32]
No effect HLA-E*01:03, 01:03 in patients and HLA-E*01:01 in donors
(116 HLA-matched unrelated donors)
[82]
Risk of  cGvHD development MICA-129 Val/Val in recipients
(211 HLA-identical HSCT sibling pairs)
[65]
Higher incidence of disease relapse MICA-129 Met/Met in recipients
(211 HLA-identical HSCT sibling pairs)
[65]
Risk of aGvHD MICA donor-recipient mismatches
(236 unrelated HSCT donor-recipient pairs)
[66]
Improved overall survival MICA and MICBdonor-recipient matches
(44 unrelated HSCT donor-recipient pairs)
[67]
Risk of aGvHD 14 bp del/del HLA-G genotype (position+2961 of 3’ UTR) in recipients (53 patients of allo-BMT) [81]
Risk of aGvHD 14 bp del/del HLA-G genotype (position+2961 of 3’ UTR) in donors (unrelated HSCT donor-recipient pairs) [83]
Decrease in the overall and disease-free survival 14 bp ins/ins HLA-G genotype in recipients
(47 recipients for allo-HSCT receiving MTX
therapy and their donors)
[80]
Table 1: Effect of non-classical HLA polymorphisms on allogeneic HSCT outcome.